<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>BELEODAQ (belinostat) for injection - for Healthcare Professionals (HCPs)</title>
    <meta name="description" content="In the next round against relapsed or refractory PTCL, fight on with BELEODAQ. It is an HDAC inhibitor available for relapsed/refractory PTCL.">
    <link rel="stylesheet" href="style/style.css">
</head>
<body>
    <header class="header">
        <!-- Indications and Usage -->
        <div class="header__indications">
            <h5 class="header__indications--title">Indications and Usage</h5>
            <p class="header__indications--body">BELEODAQ is a histone deacetylase inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.</p>
        </div>
        <!-- Navigation -->
        <nav class="header__nav">

        </nav>
    </header>
</body>
</html>